MINT-LISINOPRIL TABLET

Pays: Canada

Langue: anglais

Source: Health Canada

Ingrédients actifs:

LISINOPRIL (LISINOPRIL DIHYDRATE)

Disponible depuis:

MINT PHARMACEUTICALS INC

Code ATC:

C09AA03

DCI (Dénomination commune internationale):

LISINOPRIL

Dosage:

20MG

forme pharmaceutique:

TABLET

Composition:

LISINOPRIL (LISINOPRIL DIHYDRATE) 20MG

Mode d'administration:

ORAL

Unités en paquet:

100/500

Type d'ordonnance:

Prescription

Domaine thérapeutique:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Descriptif du produit:

Active ingredient group (AIG) number: 0121550002; AHFS:

Statut de autorisation:

CANCELLED POST MARKET

Date de l'autorisation:

2012-08-02

Résumé des caractéristiques du produit

_ _
_Page 1 of 41_
PRODUCT MONOGRAPH
PR
MINT-LISINOPRIL
lisinopril tablets
5 mg, 10 mg and 20 mg of lisinopril as lisinopril dihydrate
USP
Angiotensin Converting Enzyme Inhibitor
Manufactured for:
Mint Pharmaceuticals Canada Inc.,
1 First Canadian Place, Suite 5600
100 King Street West
Toronto, Ontario
M5X 1E2
Date of Preparation:
September 29, 2008
Submission Control No: 124991
_ _
_ _
_Page 2 of 41_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL
USE.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND
PRECAUTIONS.................................................................................
4
ADVERSE
REACTIONS.................................................................................................
10
DRUG INTERACTIONS
.................................................................................................
16
DOSAGE AND
ADMINISTRATION.............................................................................
18
OVERDOSAGE
...............................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 21
STORAGE AND
STABILITY.........................................................................................
24
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 24
PART II: SCIENTIFIC INFORMATION
..............................................................................
25
PHARMACEUTICAL
INFORMATION.........................................................................
25
CLINICAL
TRIALS...........................................................................................